Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...

The article highlights various financial dynamics within the pharmaceutical industry amid prevailing economic conditions.

Robert F. Kennedy Jr. and I rarely see eye to eye, but I’ll grudgingly admit he’s not entirely wrong about food dyes, though ...

Pharmaceutical companies in China are reportedly importing some drugs without tariffs, a sign of potential flexibility amid ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...